Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

128
Delayed Quote. Delayed Nyse - 11/24 04:00:58 pm
59.25 USD   -0.69%
4h ago MERCK : Iowa firm sign Ebola vaccine licensing deal
5h ago Merck buys rights to NewLink's experimental Ebola vaccine
7h agoDJBristol-Myers, Five Prime to Collaborate on Immunotherapy
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

06/13/2012 | 08:52am US/Eastern
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

React to this article
Latest news on MERCK & CO., INC.
4h ago MERCK : Iowa firm sign Ebola vaccine licensing deal
5h ago Merck buys rights to NewLink's experimental Ebola vaccine
7h agoDJBristol-Myers, Five Prime to Collaborate on Immunotherapy
9h ago MERCK : Submits New Drug Application to the Japanese Pharmaceuticals and Medical..
10h ago MERCK : and NewLink Genetics Enter Into Licensing and Collaboration Agreement fo..
4d ago MERCK : Dow Movers: MRK, MCD
5d ago MERCK : New Findings on Vaccines Described by Investigators at Merck & Company (..
11/17 Pfizer dampens Astra bid hopes with German Merck cancer deal
11/17 Losing Allergan deals blow to Valeant reputation
11/17 DOW MOVERS : Pfe, mrk
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF